Weight Loss Drug Meridia (Sibutramine) Comes Under Increased Scrutiny
The Food and Drug Administration (FDA) is to conduct a review of the weight loss drug Meridia (Sibutramine). A panel will meet on September 15, 2010 to decide if the drug should be withdrawn from sale in the United States.
Concerns regarding the safety of the drug were raised earlier this year, after European regulators requested Abbott Laboratories withdraw its appetite suppressant after studies revealed a link between the drug and a number of potentially fatal cardiovascular problems, including heart attacks and strokes.
Sibutramine (although approved by the FDA) is also known to increase blood pressure and/or pulse rate, making it problematic for individuals with a prior history of coronary artery disease, congestive heart failure or arrhythmias.
On August 9, 2010 the FDA announced a recall for a similar weight loss drug manufactured by EZVille, Ltd. Lab tests found that EZVille failed to declare that its Solo Slim and Solo Slim Extra weight loss drugs contained Didesmethyl Sibutramine, putting potentially thousands of consumers at risk.
If you or a loved one has suffered an adverse reaction to any prescription drug, Burg Simpson may be able to help. Call our dangerous drug attorneys toll-free 1.888.895.8020 for a free consultation.
